These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36710630)

  • 1. Development of a definition for real-world evidence using the Jandhyala method for observing consensus opinion among medical affairs pharmaceutical physicians.
    Jandhyala R
    Curr Med Res Opin; 2023 Dec; 39(12):1551-1558. PubMed ID: 36710630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a Definition for Medical Affairs Using the Jandhyala Method for Observing Consensus Opinion Among Medical Affairs Pharmaceutical Physicians.
    Jandhyala R
    Front Pharmacol; 2022; 13():842431. PubMed ID: 35273511
    [No Abstract]   [Full Text] [Related]  

  • 3. A medicine adoption model for assessing the expected effects of additional real-world evidence (RWE) at product launch.
    Jandhyala R
    Curr Med Res Opin; 2021 Sep; 37(9):1645-1655. PubMed ID: 34176383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observing expert opinion of medical affairs pharmaceutical physicians on the value of their clinical experience to the pharmaceutical industry using the Jandhyala method.
    Jandhyala R; Rout R
    Curr Med Res Opin; 2023 Dec; 39(12):1541-1550. PubMed ID: 36632732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument.
    Jandhyala R
    Pharmaceut Med; 2022 Feb; 36(1):47-57. PubMed ID: 34994965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The multiple stakeholder approach to real-world evidence (RWE) generation: observing multidisciplinary expert consensus on quality indicators of rare disease patient registries (RDRs).
    Jandhyala R
    Curr Med Res Opin; 2021 Jul; 37(7):1249-1257. PubMed ID: 33989087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea.
    Lee H; Ahn HS; Kwon S; Kang HY; Han E
    Clin Transl Sci; 2024 Apr; 17(4):e13801. PubMed ID: 38629484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making.
    Chen S; Graff J; Yun S; Beal B; Ta JT; Bansal A; Carlson JJ; Veenstra DL; Basu A; Devine B
    J Manag Care Spec Pharm; 2021 Jan; 27(1):95-104. PubMed ID: 33377442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
    Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
    F1000Res; 2018; 7():111. PubMed ID: 30026923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advancing the Real-World Evidence for Medical Devices through Coordinated Registry Networks.
    Sedrakyan A; Marinac-Dabic D; Campbell B; Aryal S; Baird CE; Goodney P; Cronenwett JL; Beck AW; Paxton EW; Hu J; Brindis R; Baskin K; Cowley T; Levy J; Liebeskind DS; Poulose BK; Rardin CR; Resnic FS; Tcheng J; Fisher B; Viviano C; Devlin V; Sheldon M; Eldrup-Jorgensen J; Berlin JA; Drozda J; Matheny ME; Dhruva SS; Feeney T; Mitchell K; Pappas G
    BMJ Surg Interv Health Technol; 2022; 4(Suppl 1):e000123. PubMed ID: 36393894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes.
    Anderson P; Higgins V; Courcy J; Doslikova K; Davis VA; Karavali M; Piercy J
    Curr Med Res Opin; 2023 Dec; 39(12):1707-1715. PubMed ID: 37933204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Evidence: A Primer.
    Dang A
    Pharmaceut Med; 2023 Jan; 37(1):25-36. PubMed ID: 36604368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Real-World Evidence in Neuroscience-Related New Drug and Biologics License Applications for Novel Therapeutics.
    Bloomfield-Clagett B; Rahman M; Smith K; Concato J
    Clin Pharmacol Ther; 2023 Nov; 114(5):1002-1005. PubMed ID: 37548904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of real-world evidence in economic assessments of pharmaceuticals in the United States.
    Lee W; Dayer V; Jiao B; Carlson JJ; Devine B; Veenstra DL
    J Manag Care Spec Pharm; 2021 Jan; 27(1):5-14. PubMed ID: 33377439
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of adding real-world evidence to regulatory submissions on the breadth of population indicated for rare disease medicine treatment by the European Medicines Agency.
    Jandhyala R
    J Pharm Policy Pract; 2022 May; 15(1):36. PubMed ID: 35509059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analyses using real-world data to generate clinical and epidemiological evidence: a systematic literature review of existing recommendations.
    Briere JB; Bowrin K; Taieb V; Millier A; Toumi M; Coleman C
    Curr Med Res Opin; 2018 Dec; 34(12):2125-2130. PubMed ID: 30217138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world evidence: perspectives on challenges, value, and alignment of regulatory and national health technology assessment data collection requirements.
    Sievers H; Joos A; Hiligsmann M
    Int J Technol Assess Health Care; 2021 Feb; 37():e40. PubMed ID: 33622423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using Real-World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward.
    Akehurst R; Murphy LA; Solà-Morales O; Cunningham D; Mestre-Ferrandiz J; de Pouvourville G
    Value Health; 2023 Apr; 26(4S):11-19. PubMed ID: 36706952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development, validation and implementation of the medical affairs pharmaceutical physician work-related quality of life instrument.
    Jandhyala R
    Curr Med Res Opin; 2023 Dec; 39(12):1567-1574. PubMed ID: 36719367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.